INTRODUCTION
Pain affects all people. Pain may be acute (e.g., injury), episodic (e.g., headaches), or chronic (e.g., sciatic pain); regardless of its nature it decreases a patient's quality of life. The annual societal cost due to lost productivity from pain is conservatively estimated at over 60 billion dollars in the United States [1] . The average worker suffering a disorder associated with pain loses 4 days of work every month compared to a half day for a worker without a pain syndrome. Thus, in addition to improving quality of life, adequate pain control could result in billions of dollars of saved productivity [1] .
This article reviews the pharmacology and toxicology of transdermal fentanyl, one of the cornerstone pharmacotherapies for patients with chronic pain. When used as directed and in a safe manner, this long-acting form of a highly-potent medication is extremely effective in controlling chronic pain. However, there are impediments to the safe use of this formulation. Both the US Food and Drug Administration (FDA) and Health Canada have warned of potential pitfalls associated with transdermal fentanyl [2, 3] . Despite these initial Public Health Advisories, the FDA continues to receive reports of fentanyl-associated life-threatening adverse events and fatalities related to inappropriate transdermal fentanyl device use [4] .
HISTORY AND BACKGROUND
Fentanyl, a schedule II medication, was introduced in 1960 to replace morphine and other opioids for use in cardiac surgery due to its higher potency (approximately 75-to 100-fold compared to morphine) [5] . It is also associated with fewer adverse cardiovascular effects than morphine and triggers substantially less histamine release. A versatile analgesic, fentanyl is now used frequently for patients with either acute or chronic pain syndromes. Acute and chronic pain are difficult to define specifically, and may coexist. Generally, acute pain begins abruptly, is severe, and is expected to persist for no longer than several days. It usually decreases in intensity during this period. Chronic pain is normally lower in intensity than acute pain, steady in intensity with some variation, and lasts longer than a week-often years.
Delivery of fentanyl for acute pain may occur by intravenous (IV), transmucosal, buccal, epidural, intrathecal, or inhalational routes [6] [7] [8] [9] . The pharmacokinetics and clinical effects of fentanyl by these routes in the medical setting are predictable and the drug is considered safe when used by appropriately trained clinicians. However, for practical and pharmacokinetic reasons, fentanyl is indicated for transdermal administration only for the treatment of chronic pain, and generally for use in the outpatient setting. Millions of patients have used a transdermal fentanyl device, also known as the fentanyl patch, to control their chronic pain since approval in 1990 of this medication delivery system by the FDA. Prior to this approval, chronic opioid analgesic therapy was largely limited to oral agents or more invasive means of providing continuous, controlled drug dosing. The transdermal fentanyl device allows opioid analgesia to be provided in a discreet, convenient, noninvasive, and generally safe manner [10] [11] [12] .
Transdermal delivery of fentanyl was initially studied during the late 1980s in the postoperative setting [13] [14] [15] [16] [17] [18] , where its safety and efficacy could be evaluated under controlled clinical conditions and with intensive monitoring. Soon thereafter, clinical trials demonstrated that transdermal fentanyl was safe and efficacious for the outpatient treatment of chronic cancer pain [19] [20] [21] [22] [23] [24] , and subsequently for other pain syndromes. Interestingly, the use of transdermal fentanyl in the postoperative setting is now contraindicated in the prescribing information, though in practice it is occasionally still used by some pain management specialists. The transdermal fentanyl device must be differentiated from patient-controlled iontophoretic transdermal fentanyl delivery systems [25, 26] .
Adverse events due to transdermal fentanyl device use can be divided into three general categories based largely on intent of use: appropriate therapeutic use, inappropriate therapeutic use (misuse), and abuse. Appropriate therapeutic use is defined as a prescribed use for an appropriate clinical condition in which both the physician and patient use the transdermal device as described by the manufacturer's guidelines. Misuse is defined as misguided use for therapeutic purposes, and may be intentional or unintentional. Misuse may be attributed to either the physician or the patient and includes, for example, prescribed use for an acute pain syndrome by an inadequately informed physician or the intentional application of multiple transdermal devices by a patient for enhanced analgesia [2, 4, [27] [28] [29] . In one report a physician, in an attempt to decrease the dose, improperly advocated that his patient cut the transdermal device into quarters before applying it [30] . Abuse is defined as the intentional inappropriate use of the transdermal device, or its contents, for purposes other than those for which the transdermal device was intended or prescribed. This is typically done with euphoric intent, though it may occasionally be for suicidal reasons.
ADVERSE EVENTS REPORTS OF TRANSDERMAL FENTANYL
Sales of Johnson & Johnson's (Janssen) Duragesic transdermal devices have steadily increased since its introduction, and had surpassed 4 million prescriptions and nearly 2 billion dollars in 2004, though sales have fallen with the introduction of generics. Not surprisingly, there has been a concomitant increase in adverse events and emergency department (ED) visits related to the transdermal fentanyl device [31, 32] . The reasons for this are unclear and likely multifactorial. In 2004, the Drug Abuse Warning Network (DAWN), a national surveillance database, reported over 8,000 ED visits in the United States due to the misuse of transdermal fentanyl [31, 32] . This number is likely an underestimate, due to the level of reliability in coding for the various opioids and to the selective and voluntary nature of hospital participation in DAWN.
Although individual case reports confirm the abuse of fentanyl derived from the transdermal delivery system, epidemiological links are less clear. Fentanyl use data is collected by various groups including the Drug Enforcement Administration (DEA), DAWN, and medical examiners [33, 34] . Although the latter data are fatality related, they often inadequately distinguish between misuse and abuse, and generally fail to specify the form and/or route by which fentanyl was utilized. A more obvious association from the medical examiner literature is the utilization of the transdermal fentanyl delivery systems as a method of suicide [27, 35, 36] . While in many cases the cause of death may be confirmed objectively, deciphering the manner of death to determine who died from fentanyl abuse rather than suicide is often difficult. This decision is largely based on scene investigation, available clinical history and findings, and postmortem determinations, including analytical toxicology testing. However, even determining that fentanyl is the cause of death on the basis of postmortem blood fentanyl concentrations is occasionally fraught with difficulty. For example, as discussed later, pharmacodynamic effects, such as opioid tolerance, and pharmacokinetic effects, such as postmortem redistribution, complicate the interpretation of the postmortem blood concentration [27] . See the Relevant Forensic Toxicology section below for further discussion.
CLINICAL PHARMACOLOGY OF TRANSDERMAL FENTANYL PATCHES
Fentanyl possesses many of the physicochemical properties essential for transdermal use [37] . The molecular weight of fentanyl base is 337 Da [38] within the maximum molecular weight considered suitable for skin permeation (< 1000 Da). Fentanyl, unlike morphine and other opioids, is highly potent, and produces desired clinical effects following the systemic absorption of a fraction of a milligram in nontolerant individuals. It is typically considered that drug administration by this route is limited to drugs that are effective at doses of <2 mg daily [39] .
Additionally, fentanyl is sufficiently soluble in both the lipid and aqueous compartments of the skin to allow penetration. In its alkaloid (base) form, fentanyl readily enters the keratinaceous stratum corneum. This layer of the epidermis provides the greatest barrier to the movement of water both into and out of the body [40] . Only substances with sufficient lipid solubility can dissolve and diffuse past the ceramides and other waxy lipids of this dermal layer. Subsequent movement of drug from the lipid layer into the aqueous dermis is required to enable systemic absorption. Thus a chemical must be soluble in both lipid and water to be internalized effectively following dermal application. The relationship between the lipid and water solubility of a chemical is numerically demonstrated by its octanol-water partition coefficient. This is expressed as the concentration ratio of a chemical in octanol and in water while at equilibrium at a given temperature. Fentanyl base has an octanol-water partition coefficient of 860 (fentanyl citrate is 717 at pH 7.4), thus passes through the lipid portion of the epidermis with relative ease. Although fentanyl base and salt (citrate) are similarly bioavailable, the systemic absorption of the base appears to be slightly faster [40] . In comparison, morphine is not very lipophilic and possesses an octanolwater partition coefficient of 0.7, and predictably demonstrates poor epidermal permeability [37] .
The high lipophilicity of fentanyl results in a rapid diffusion into the lipophilic epidermal tissue with subsequent slow movement into the water-rich dermal tissue (Figure 1) . This results in the formation of a depot in the keratinaceous layer of the epidermis. This depot formation accounts for the slow onset and prolonged effects of transdermally-delivered fentanyl. Transdermal device application sites are typically rotated in part to prevent serum concentration fluctuations resulting from the development of large depots following consecutive use of the same site.
Other dermal variables affect the rate of transdermal fentanyl absorption. For example, variations in skin thickness and degree of keratinization will alter its systemic bioavailability and account for much of the great interindividual variability observed with transdermal fentanyl absorption [41] [42] [43] . This can be seen in Figure 2 , in which there is a wide range around the mean serum fentanyl concentration in transdermal fentanyl users. The average skin thickness of the human body is 40 μm, but ranges between 20 and 80 μm based on location, race, age, and gender, among other factors. In skin samples from 8 individuals, there was a >50% difference in the permeability of fentanyl [44] . Skin surface areas with similar stratum corneum thickness typically possess similar diffusion rates within an individual, explaining why the chest, extremities, and abdomen are acceptable sites for transdermal device application without the need for any dosage changes [41, 44] . Following application of a transdermal fentanyl device to broken skin, blood fentanyl concentrations can rise 5-fold [42] . Exposed tissue lacking a stratum corneum, such as mucosa, has a >30-fold increase in fentanyl absorption, and more predictable pharmacokinetics [45] . This effect permits the successful use of fentanyl citrate lozenges (Actiq) or buccal tablets (Fentora) for sedation and short-term analgesia, while explaining the potential for morbidity and mortality associated with improper use [46] . Correspondingly, fatal overdose may result from buccal mucosal application of transdermal fentanyl devices [47] [48] [49] [50] [51] .
Skin temperature elevation enhances the absorption of transdermally-applied fentanyl, perhaps either as a result of cutaneous vasodilation or of enhanced solubility of fentanyl [51] [52] [53] . An increase in skin temperature from 32°C to 40°C leads to a gradual 10-to 15-fold increase in cutaneous blood flow [54] . A 3°C increase in body temperature raises the peak fentanyl blood concentration by 25% [42] . Case reports detail that elevation in skin or ambient temperatures from external sources such as hot tubs or heating blankets may lead to fentanyl overdose [4, 37, 55, 56] . Although blood fentanyl concentrations are often not provided in case reports, a controlled study using a 25 μg/hour transdermal fentanyl device showed that the concentration rose rapidly when the transdermal device on the skin was heated to 42°C [52] . Application of an overlay to hold in place a nonsticking transdermal device may be associated with altered fentanyl absorption, and raises the potential for toxicity [57] . Further study is essential to determine whether exercise produces dramatic increases in the rate and extent of transdermal absorption, as is demonstrated for the ultrapotent fentanyl analog sufentanil [39] .
Intravenously administered fentanyl has a half-life of 2-4 hours but a short duration of action of approximately 15 minutes, due primarily to redistribution [58] . Extensive first-pass hepatic metabolism limits its oral bioavailability [59] . Based on the data provided in the transmucosal fentanyl labeling (Actiq), about 50% of transmucosal fentanyl is absorbed, with half of this absorbed transmucosally and 25% escaping first-pass elimination after swallowing [59] . Bypassing the liver explains why the bioavailability of transdermal fentanyl is excellent (~92%), which has both advantages and potential liabilities [45, 60, 61] . Once absorbed, fentanyl, like other lipophilic compounds, achieves a large volume of distribution (6 L/kg [range 3-8]) [38] .
Fentanyl is a pure mu-opioid receptor agonist that demonstrates approximately 75-100 times the potency of morphine. Its high lipophilicity allows it to readily cross the blood-brain barrier to produce analgesia and sedation. Alterations in blood pH may affect the distribution of fentanyl between plasma and the central nervous system (CNS) [38] .
Metabolism occurs primarily via oxidative dealkylation by hepatic CYP 3A4 to norfentanyl and other less active or inactive metabolites through an oxidative N-dealkylation process. The concomitant use of fentanyl with cytochrome CYP 3A4 inhibitors (e.g., ketoconazole, ritonavir, nefazodone) may result in an increase in both plasma fentanyl concentrations and the risk of adverse drug effects [2, 4] . A small amount (8%) of fentanyl is eliminated unchanged in the urine [38] .
TRANSDERMAL DELIVERY SYSTEMS
There are two general types of transdermal delivery systems currently in clinical use (Figure 3) . The original transdermal therapeutic system (TTS), also called the reservoir transdermal device (made by Jannsen [Duragesic] and generics by Sandoz, Watson, Pricara, and Actavis) consists of four functional layers and a protective peel strip [38] . Each of these layers provides important qualities to facilitate consistent and continuous diffusion of fentanyl over a 72-hour period while minimizing the likelihood of toxicity. The first layer is a polyester film backing that prevents leakage of transdermal device contents onto the surrounding skin. The second layer consists of a drug reservoir, which contains fentanyl and ethanol combined with a hydroxycellulose gel. Ethanol contained within this gel acts as an organic solvent to approximately double the rate of diffusion of fentanyl into the stratum corneum [62] . The quantity of fentanyl contained in this reservoir is appropriate to provide a sufficient concentration gradient for transdermal absorption throughout a 3-day cutaneous application ( Table 1) .
This reservoir accounts for much of the abuse potential of this transdermal device and for the possibility of dangerous leakage onto nearby skin, both discussed below.
The third layer, an ethylene vinyl acetate copolymer rate-controlling membrane, regulates the rate of delivery of fentanylethanol mixture to the skin surface. This reduces the variations in dermal transport and effectively slows diffusion and subsequent absorption by about 50%, an effect most important for those in the population who possess faster-than-average transdermal absorption [38, 42, 44, 45] . It allows 2.5 μg of fentanyl to diffuse across each square centimeter of transdermal device per hour. Thus, a 100 μg/hour transdermal device is constructed to have a skin surface area exposure of 40 cm 2 (see Table 1 ) [63] . The silicone skin adhesive represents the last layer of the transdermal fentanyl device, providing a nonirritating and secure surface area of skin contact. By containing fentanyl itself, the adhesive facilitates the development and maintenance of therapeutic fentanyl concentrations following initial transdermal device application and each subsequent change, respectively. The diffusion that occurs from this silicone adhesive layer also demonstrates that transdermal fentanyl absorption occurs in the absence of an ethanol copolymer [39, 45] .
More recently introduced to the market, the fentanyl transdermal system (FTS; the generic device by Mylan), commonly called the matrix patch, consists of two functional layers and a protective peel strip. The two functional layers are a backing layer of polyolefin film and a fentanyl-containing silicone adhesive layer. The major difference from the TTS is the absence of a fluid fentanyl reservoir and therefore the ethanol coadsorbant. The pharmacokinetics and clinical effects of the matrix transdermal device are purportedly similar to that of the original transdermal device despite the absence of a reservoir and a rate-controlling membrane [64] . This suggests that skin contact is a consequential variable in determining the absorption pharmacokinetics of fentanyl. Interestingly, the FDA did not require additional pharmacological data prior to approving the generic matrix transdermal device despite this distinct design difference. The prescribing information is essentially identical for the two transdermal devices [65] . This approach raised debate among the various producers of transdermal fentanyl products regarding the appropriateness of accepting the prescribing information for the initial transdermal fentanyl delivery system as representative of the generic product despite a distinct release mechanism [66] [67] [68] .
Application of fentanyl to the skin in an alternative transdermal device (transdermal fentanyl delivery system [FTDS]) that does not have the same rate-limiting membrane as the reservoir transdermal device results in more rapid and more variable absorption as well as a higher complication rate [69] . This highlights the role for the rate limiting membrane in the transdermal device in controlling the functional bioavailability of fentanyl. This experimental transdermal device, containing about 9 mg of fentanyl, resulted in a 20-fold range in plateau plasma concentrations (0.34-6.75 ng/mL); 3 of 14 patients were withdrawn from the study due to consequential opioid poisoning [69] . Another transdermal delivery system consisting of fentanyl dissolved in dipropylene glycol within a silicone matrix has similar pharmacokinetic qualities as the reservoir transdermal device [70] .
PHARMACOKINETICS OF THE TRANSDERMAL FENTANYL DEVICE
Fentanyl becomes detectable in the serum within 1-2 hours of application of a transdermal fentanyl device. However, therapeutic serum fentanyl concentrations are not achieved until approximately 12-16 hours after transdermal device application [16, 61, 71, 72] . The mean time to maximal serum concentrations
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JOURNAL OF MEDICAL TOXICOLOGY I VOLUME 5, NUMBER 4 I DECEMBER 2009 One of the advantages of this form of fentanyl delivery is exemplified by the relatively smooth pharmacokinetic curve of blood fentanyl concentrations that is produced by transdermal device delivery, particularly when compared to intermittent dosing by virtually any other route. Figure 2 demonstrates that the mean curve of serum fentanyl concentration is relatively flat over the 3-day period following reaching steady state, without the peaks and troughs typical of intermittent dosing. There is a somewhat wide range between the minimum and maximum serum concentrations attained, highlighting the importance of close observation during the initiation of this therapy. Elderly patients have a slightly longer time to peak concentration and a prolonged half-life following removal of the transdermal device [77] . In 1.5-to 5-year-old patients, the fentanyl plasma concentrations were approximately twice as high as that of adult patients [38] . In older pediatric patients, the pharmacokinetic parameters were similar to that of adults. A review of the use of the reservoir transdermal device in children undergoing treatment for cancerrelated pain suggests that individual pharmacokinetics parameters of transdermal fentanyl seem to differ from adults (e.g., longer time to reach steady-state serum concentrations, higher weightbased clearance), safety concerns remain, and there is a significant need for additional information [78] . The effects of cachexia, muscle wasting, or other debilitating diseases on fentanyl pharmacokinetics are not well studied.
CLINICAL EFFECTS
The clinical effects of fentanyl, regardless of route of administration, are similar to those of other opioids, and are similarly dependent on both the dose and the degree of patient tolerance. At serum fentanyl concentrations of 0.63-1.5 ng/mL, postoperative analgesia is produced in most opioid-naïve patients [15] . Hypoventilation begins to manifest at concentrations >1.5 ng/mL, a subtherapeutic serum concentration for some [79] [80] [81] .
With escalating doses, analgesia is preserved and mild sedation is noted. Patients in this state are easily arousable with physical stimulation. As concentrations increase further, deep sedation develops, requiring greater stimulation, and the arousal period shortens. Further increasing fentanyl concentrations produces coma, with the inability to arouse the patient. Respiratory depression essentially parallels sedation and analgesia, with the eventual development of apnea. Simultaneous loss of protective airway reflexes highlights the requirement for advanced ventilatory management skills. Serum fentanyl concentrations of 3.0 ng/mL typically produce these latter effects in opioid-naïve patients.
Miosis is a common side effect and may be used diagnostically to identify both compliance and overdose. Gastrointestinal effects, dyspnea, and pruritis can be discomforting [82] . The rigid chest syndrome associated with fentanyl infusion is not well described with the transdermal fentanyl device. This may be related to the slower rate of rise of the serum levels with transdermal fentanyl devices than with IV infusion [83] . Mydriasis, vomiting and diarrhea, and piloerection may be used to identify opioid withdrawal.
THERAPEUTIC CONSIDERATIONS
The maintenance of a relatively steady serum concentration with transdermal fentanyl, which is particularly difficult for drugs with short half-lives, results in reduced side effects and improved efficacy. This improves therapeutic compliance, which is perhaps less of an issue with analgesics than with other transdermally-administered drugs (e.g., estrogen, clonidine). However, in patients with chronic pain, the substitution of transdermal fentanyl for other opioids is often considered as much for convenience (e.g., reduced dosing frequency, covert use) as for any specific analgesic benefit. This highlights the importance of weighing the overall therapeutic benefit of a drug and its delivery system against its overall safety aspects in the associated risk-benefit analysis.
Several approaches have been developed for initiating transdermal fentanyl therapy, but central to all is the presupposition of preexistent opioid tolerance [38] . The transdermal fentanyl device should only prescribed for patients who are already receiving long-term therapy with strong oral or parenteral opioids (strong opioids include morphine and oxycodone, not codeine). Tolerance in this situation is difficult to define quantitatively, but it is often suggested that the patient should be on at least the equivalent of morphine 60 mg daily for more than a week (this can be, for example, at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily for this period of time) [38] . Due to the interindividual pharmacokinetic differences as well as the dose-response (pharmacodynamic) variability, the process of initiating transdermal fentanyl therapy is often associated with unpredictable clinical responses. As in the use of methadone, a long-acting oral opioid, the initiation of therapy prior to the development of steady-state pharmacokinetics may be the period of greatest risk. Determination of an appropriate starting dose of the transdermal fentanyl device can be complex, and incorrect selection of the dose may result in over-or underdosing. Because of this concern, patients may be initiated on transdermal therapy in the hospital. Conversion tables exist for calculating an expected transdermal fentanyl device dose requirement for patients on prior chronic oral opioid therapy [38] . Dose finding is often necessary, and short-acting opioid adjunctswhether oral or IV-will often be necessary to control pain until therapeutic serum fentanyl concentrations are achieved, and often afterwards.
Several recent literature reports suggest that certain patients who are not tolerant to strong opioids, and even opioid-naïve patients, may safely receive a low-dose transdermal fentanyl device [84, 85] . The approach of slowly escalating from a 12.5 or 25 μg/hour transdermal device should provide a degree of safety from opioid overdose. This approach requires specialized knowledge and a highly-selected patient population, and is inconsistent with most current guidelines for the initiation of a transdermal fentanyl device. In addition, physician knowledge of appropriate transdermal fentanyl use is generally poor, and recent reports raise concerns about the use of these delivery systems without an adequate understanding of their pharmacology and toxicology [71, 86] .
Patients with acute pain syndromes are not appropriate candidates for transdermal fentanyl [38] . This group risks developing opioid toxicity as their acute painful stimulus, and its associated analgesic requirements, resolves. This time-limited pain syndrome is incompatible with the predicted pharmacokinetics of the transdermal fentanyl device (see above). The package insert for the transdermal fentanyl device [38] and several FDA advisories [2,4] specifically note the contraindication of transdermal fentanyl to control postoperative pain. However, some pain specialists advocate transdermal fentanyl for postoperative pain using extreme caution and close clinical monitoring.
Considering the time involved to attain a new steady-state serum fentanyl concentration after dose escalation (approximately 3-5 days) stacking of sequential doses with resultant fentanyl toxicity may occur. This delay to steady-state kinetics illustrates the importance of the utilization of short-acting opioids during both the initiation and transitioning of transdermal fentanyl device doses [38] .
Even among opioid-tolerant patients, starting any strength transdermal device outside of the hospital or with a transdermal device that delivers greater than 25 μg/hour should be done with great caution and is discouraged [38] . Subsequent dosing increases would also ideally occur in small increments (perhaps in the hospital), only after the previous transdermal device had been applied for 3 days.
INTENTIONAL TRANSDERMAL FENTANYL DEVICE MISUSE AND ABUSE
Fentanyl is reportedly commonly abused by healthcare professionals [87] and its analogues have been implicated in several large epidemics of "heroin" poisoning [88] . Fentanyl abusers note that it produces euphoric effects that are similar to heroin [89] . Transdermal fentanyl devices are suitable for abuse in several ways. The fluid state of the drug reservoir layer allows fentanyl to be extracted. Every transdermal device, even after being used, contains a significant quantity of fentanyl. Even the smallestdose transdermal device contains 1.25 mg (or 1250 μg) of fentanyl (see Table 1 ). This is 10-20 times the typical initial IV therapeutic dose of 50-100 μg [1 μg/kg] used during procedural analgesia and sedation. Many of the fatalities reported from abuse of the transdermal fentanyl device are associated with IV administration of the fentanyl-containing gel extracted from the reservoir transdermal device [35, [90] [91] [92] [93] [94] . One interesting report based on information from a street user suggests that the matrix transdermal device is preferred over the reservoir transdermal device by Canadian opioid abusers [95] . By cutting the matrix transdermal device into the desired size, users can place the fragment in their mouth, allowing rapid transmucosal absorption [67] . Fentanyl may also be eluted from the transdermal device using solvents and then injected [67] . Similar reports can be found on the Internet (e.g., http://www.bluelight.ru).
Other reported routes of abuse include inhalation of a pyrolyzed transdermal device, insertion of a transdermal device rectally, and drinking water in which a transdermal fentanyl device was steeped as a tea bag [96] [97] [98] . Despite its poor oral bioavailability, ingestion of fentanyl gel may result in poisoning and death [35, 48, 50, 99, 100] . It remains unclear to what extent transdermal device ingestion-related fatalities are due to sublingual, transmucosal, or gastrointestinal absorption, or a combination thereof. Fentanyl in other formulations intended for transmucosal absorption (e.g., Fentora, Actiq) has resulted in fentanyl morbidity and mortality [59, 101] . Even accounting for fentanyl's poor enteral bioavailability, each transdermal device contains a sufficient amount of fentanyl to be lethal.
Previously-worn transdermal devices may contain 28-84% of the initial drug [102] . Transdermal fentanyl devices have been reportedly removed from decedents and nursing home patients for subsequent abuse [103] , prompting healthcare facilities to develop policies for their safe disposal. Exposure to discarded or misplaced transdermal devices has also proven consequential [100] . The manufacturers and FDA have gone to substantial lengths to educate patients (e.g., fold the sticky side together and flush down a toilet) and provide safe mechanisms for transdermal device use and disposal, largely to prevent unintentional childhood exposure to discarded transdermal devices [4, 100, 104, 105] .
TRANSDERMAL DEVICE LEAK
Concerns for dysfunction of the TTS polyester backing with subsequent fentanyl poisoning following gel leakage onto intact skin prompted the manufacturers to issue an "urgent product recall" in 2004 of more than 2 million transdermal devices [106, 107] . They noted the possibility that "a small percentage of these transdermal devices which were distributed in the U.S. may leak medication along one edge" due to a "fold over defect" of the backing material, which occurred during the manufacturing process. The company estimated that <19,000 transdermal devices out of a lot total of 440,000 (~5%) were potentially defective. Reservoir leak-age during clinical use could cause the fentanyl-containing gel to spread over the skin, increasing the surface area for absorption and also accelerating the evaporation of the alcohol and water solvents of the gel. Currently undefined, this evaporative process may speed or slow the delivery of fentanyl across the epidermis. Although improved manufacturing practices and strict quality assurance procedures were implemented by the manufacturers, two additional recalls due to potential membrane defects were issued in early 2008 [108,109] .
RELEVANT FORENSIC TOXICOLOGY
The most consistent pathological finding on postmortem examination is pulmonary edema [110] , and as with other opioid fatalities, such as heroin or methadone, the nonspecific pathology findings require that the determination of the cause of death await the toxicological analysis. In many of the transdermal fentanyl fatality reports the clinical exposures are inadequately detailed (or not readily discernable), which may increase the complexity of the cause of death determination. Additionally, many of these reports involve concomitant exposures to other substances in often undefined concentrations, hampering the ability to fully appreciate the role of fentanyl. Because of the lack of structural similarity, fentanyl should not be expected to produce a positive result on the opioid/opiate component of a standard immunoassay-based "urine drug screen" [111] . Liquid chromatography-mass spectrometry is the established standard for measuring serum fentanyl concentrations [112] .
In a large series of fatalities from fentanyl abuse (not transdermal device-related), the mean postmortem blood concentration was 3 ng/mL [110] . Another similar series reported a range in serum concentration of 5-120 ng/mL, with a median of 22 ng/mL, in 19 fatalities deemed to be due to drug overdose, though not necessarily abuse related [113] . Several of the deaths were associated with transdermal fentanyl delivery systems; one patient on a transdermal fentanyl dose of 300 μg/hour had a postmortem blood fentanyl concentration of 120 ng/mL.
The mean measured fentanyl blood concentration in 6 transdermal fentanyl fatalities was 21 ng/mL (10-38 ng/mL) [35] In a series of 25 deaths potentially involving transdermal fentanyl, the 8 cases felt to be "clearly not related" had heart blood concentrations of <2-7 ng/mL, while in the 12 cases considered attributable solely to fentanyl the heart blood concentrations ranged from 16 to 139 ng/mL [27] . Postmortem redistribution is considered to be minor, though variable, with a heart/femoral ratio of 1.6 (range 0.7-4.6) noted in a study of 13 transdermal fentanyl device-related fatalities [27] .
In one reported case, in which an elderly woman applied 10 transdermal fentanyl devices simultaneously in a successful suicide attempt, the femoral blood concentration was 21.3 ng/mL in right femoral blood, 37.6 ng/mL in right ventricular blood, and 33.9 ng/mL in left ventricular blood. Corresponding norfentanyl concentrations were <2 ng/mL, 4.2 ng/mL, and 4.4 ng/mL, respectively [29] . An 83-year-old woman who had three 100 μg/hour transdermal devices on her skin had a blood fentanyl concentration of 25 ng/mL [36] . Injection administration from a transdermal fentanyl device resulted in blood fentanyl concentrations of 2.7 ng/mL and 13.8 ng/mL in 2 decedents who extracted the drug from a 100 μg/hour transdermal device [94] .
Although it would not be surprising that transdermal fentanyl device injection abuse would result in higher blood concentrations than with transdermal use, in one study of 23 transdermal fentanyl device-related deaths, the fatalities associated with a transdermal route of poisoning had higher mean blood fentanyl concentrations (21 ng/mL) than those with an IV route (7 ng/mL) [35] .
In a series of 25 deaths potentially involving transdermal fentanyl, those "clearly not related" had liver concentrations of 5.8-31 ng/g while those deemed fentanyl related had concentrations of 69-352 ng/g. 27 Following oral ingestion of a used 25 μg/hour transdermal fentanyl delivery system, a 1-year-old girl had the following fentanyl and norfentanyl concentrations: peripheral blood, 5.6 and 5.9 ng/mL; heart blood, 19.0 and 8.9 ng/mL; and liver, 235 and 26 ng/g [100] . This suggests that although first-pass hepatic metabolism is substantial, poisoning following transdermal device ingestion remains a concern.
MANAGEMENT OF FENTANYL POISONING
The management of fentanyl poisoning, whether transdermal or another route, should focus on ventilatory support and oxygenation first and foremost. This is most typically provided by bagvalve-mask ventilation, although endotracheal intubation or other measures (e.g., laryngeal mask airway) may be needed in some patients. Although naloxone effectively antagonizes fentanyl at the mu-opioid receptor and may avoid intubation in many, it may be avoided best in mildly-poisoned, nonvomiting, opioid-tolerant patients with adequate spontaneous ventilation. Patients provided solely supportive care will not awaken immediately, which may not prove satisfactory to the clinical staff. However, administration of naloxone in conventional (0.4-2 mg) dose to this latter group of patients is associated with fulminant awakening and precipitated opioid withdrawal, with its attendant complications [114] . In addition, recrudescence of an underlying pain syndrome, if present, may be undesirable. Judicious titration, starting at very low doses (e.g., 0.05 mg IV), while providing ventilatory support and oxygenation, may provide a more gradual, and safer, awakening. Failure to arouse with an appropriately-titrated dose of naloxone may signal the presence of an overlooked diagnosis, such as a concomitant exposure or cerebral hypoxia. Due to the high potency of fentanyl, higher-than-conventional doses of naloxone may be required on rare occasions.
Although the transdermal fentanyl device should be immediately removed, this is inadequate monotherapy as the reservoir of fentanyl in the stratum corneum will continue to deliver fentanyl systemically for several hours [38] . Although the skin should be cleansed to remove any external drug, the rapidity of absorption makes the benefit of this questionable. Additionally, cleansing would likely have limited or no effect on removing intradermal fentanyl. The optimal cleansing compound is undefined, and soap and water are likely acceptable. It would be appropriate to completely examine the patient for the presence of an unsuspected transdermal fentanyl device.
CONCLUSION
Fentanyl is an extremely potent opioid carrying significant analgesic benefit, but capable of causing considerable harm. Furthermore, transdermal administration of fentanyl extends many of the drug's therapeutic benefits, but also adds unique factors that may complicate the drug's safety. There are many reasons for the enhanced toxicity, including inappropriate prescription and improper use. As a potent opioid analgesic in a concentrated transdermal device system, its abuse potential is extremely high and carries a high risk of morbidity or mortality. Physician education and awareness concerning the numerous and often resourceful ways with which transdermal fentanyl may be misused or abused hopefully will result in fewer poor outcomes and ultimately save lives.
